Prelude Therapeutics Stock Today
| PRLD Stock | USD 0.74 0 0.41% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Prelude Therapeutics is trading at 0.73699999 as of the 21st of March 2025, a 0.41 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.74. Prelude Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of September 2020 | Category Healthcare | Classification Health Care |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. The company has 42.3 M outstanding shares of which 3.1 M shares are at this time shorted by private and institutional investors with about 11.06 trading days to cover. More on Prelude Therapeutics
Moving together with Prelude Stock
Moving against Prelude Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Prelude Stock Highlights
| President Officer | Edna MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPrelude Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Prelude Therapeutics' financial leverage. It provides some insight into what part of Prelude Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prelude Therapeutics (PRLD) is traded on NASDAQ Exchange in USA. It is located in 175 Innovation Boulevard, Wilmington, DE, United States, 19805 and employs 131 people. Prelude Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.66 M. Prelude Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 42.3 M outstanding shares of which 3.1 M shares are at this time shorted by private and institutional investors with about 11.06 trading days to cover.
Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Prelude Therapeutics Probability Of Bankruptcy
Ownership AllocationPrelude Therapeutics owns a total of 42.3 Million outstanding shares. Over half of Prelude Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Prelude Ownership Details
Prelude Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 402.3 K | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 392.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 365.2 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 300 K | |
| State Street Corp | 2024-12-31 | 293.4 K | |
| Two Sigma Investments Llc | 2024-12-31 | 231.8 K | |
| Rhumbline Advisers | 2024-12-31 | 166.8 K | |
| Td Asset Management Inc | 2024-12-31 | 160.7 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 148.3 K | |
| Orbimed Advisors, Llc | 2024-12-31 | 10.9 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 10.1 M |
Prelude Therapeutics Historical Income Statement
Prelude Stock Against Markets
Prelude Therapeutics Corporate Management
| WanJen MD | Senior Development | Profile | |
| Laurent MBA | Chief Officer | Profile | |
| William MD | Senior Development | Profile | |
| Naveen Babbar | Senior Medicine | Profile | |
| Neelesh MD | VP Devel | Profile | |
| Aimee Crombie | Senior Operations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.